Screening for candidate hepatic growth factors by selective portal infusion after canine Eck's fistula

Antonio Francavilla, Thomas E. Starzl, Ken Porter, Carlo Scotti Foglieni, George K. Michalopoulos, Guiseppe Carrieri, Jose Trejo, Alessandro Azzarone, Michele Barone, Qi Hua Zeng

Research output: Contribution to journalArticle

71 Citations (Scopus)

Abstract

Completely diverting portacaval shunt (Eck's fistula) in dogs causes hepatocyte atrophy, disruption of hepatocyte organelles, fatty infiltration and lowgrade hyperplasia. The effect of hepatic growth regulatory substances on these changes was assessed by constantly infusing test substances for four postoperative days after Eck's fistula into the detached left portal vein above the shunt. The directly infused left lobes were compared histopathologically with the untreated right lobes. In what has been called an hepatotrophic effect, stimulatory substances prevented the atrophy and increased hepatocyte mitoses. Of the hormones tested, only insulin was strongly hepatotrophic; T3 had a minor effect, and glucagon, prolactin, angiotensin II, vasopressin, norepinephrine and estradiol were inert. Insulin-like growth factor, hepatic stimulatory substance, transforming growth factor-α and hepatocyte growth factor (also known as hematopoietin A) were powerfully hepatotrophic, but epidermal growth factor had a barely discernible effect. Transforming growth factor-β was inhibitory, but tamoxifen, interleukin-1 and interleukin-2 had no effect. The hepatotrophic action of insulin was not altered when the insulin infusate was mixed with transforming growth factor-β or tamoxifen. These experimens show the importance of in vivo in addition to in vitro testing of putative growth control factors. They illustrate how Eck's fistula model can be used to screen for such substances and possibly to help delineate their mechanisms of action.

Original languageEnglish
Pages (from-to)665-670
Number of pages6
JournalHepatology
Volume14
Issue number4 PART 1
Publication statusPublished - Oct 1991

Fingerprint

Surgical Portacaval Shunt
Canidae
Intercellular Signaling Peptides and Proteins
Transforming Growth Factors
Hepatocytes
Liver
Tamoxifen
Insulin
Atrophy
Hematopoietic Cell Growth Factors
Growth Substances
Hepatocyte Growth Factor
Somatomedins
Portal Vein
Glucagon
Vasopressins
Interleukin-1
Mitosis
Epidermal Growth Factor
Angiotensin II

ASJC Scopus subject areas

  • Hepatology

Cite this

Francavilla, A., Starzl, T. E., Porter, K., Foglieni, C. S., Michalopoulos, G. K., Carrieri, G., ... Zeng, Q. H. (1991). Screening for candidate hepatic growth factors by selective portal infusion after canine Eck's fistula. Hepatology, 14(4 PART 1), 665-670.

Screening for candidate hepatic growth factors by selective portal infusion after canine Eck's fistula. / Francavilla, Antonio; Starzl, Thomas E.; Porter, Ken; Foglieni, Carlo Scotti; Michalopoulos, George K.; Carrieri, Guiseppe; Trejo, Jose; Azzarone, Alessandro; Barone, Michele; Zeng, Qi Hua.

In: Hepatology, Vol. 14, No. 4 PART 1, 10.1991, p. 665-670.

Research output: Contribution to journalArticle

Francavilla, A, Starzl, TE, Porter, K, Foglieni, CS, Michalopoulos, GK, Carrieri, G, Trejo, J, Azzarone, A, Barone, M & Zeng, QH 1991, 'Screening for candidate hepatic growth factors by selective portal infusion after canine Eck's fistula', Hepatology, vol. 14, no. 4 PART 1, pp. 665-670.
Francavilla A, Starzl TE, Porter K, Foglieni CS, Michalopoulos GK, Carrieri G et al. Screening for candidate hepatic growth factors by selective portal infusion after canine Eck's fistula. Hepatology. 1991 Oct;14(4 PART 1):665-670.
Francavilla, Antonio ; Starzl, Thomas E. ; Porter, Ken ; Foglieni, Carlo Scotti ; Michalopoulos, George K. ; Carrieri, Guiseppe ; Trejo, Jose ; Azzarone, Alessandro ; Barone, Michele ; Zeng, Qi Hua. / Screening for candidate hepatic growth factors by selective portal infusion after canine Eck's fistula. In: Hepatology. 1991 ; Vol. 14, No. 4 PART 1. pp. 665-670.
@article{66dc7bea8b8c4a898a640a5f198f3c45,
title = "Screening for candidate hepatic growth factors by selective portal infusion after canine Eck's fistula",
abstract = "Completely diverting portacaval shunt (Eck's fistula) in dogs causes hepatocyte atrophy, disruption of hepatocyte organelles, fatty infiltration and lowgrade hyperplasia. The effect of hepatic growth regulatory substances on these changes was assessed by constantly infusing test substances for four postoperative days after Eck's fistula into the detached left portal vein above the shunt. The directly infused left lobes were compared histopathologically with the untreated right lobes. In what has been called an hepatotrophic effect, stimulatory substances prevented the atrophy and increased hepatocyte mitoses. Of the hormones tested, only insulin was strongly hepatotrophic; T3 had a minor effect, and glucagon, prolactin, angiotensin II, vasopressin, norepinephrine and estradiol were inert. Insulin-like growth factor, hepatic stimulatory substance, transforming growth factor-α and hepatocyte growth factor (also known as hematopoietin A) were powerfully hepatotrophic, but epidermal growth factor had a barely discernible effect. Transforming growth factor-β was inhibitory, but tamoxifen, interleukin-1 and interleukin-2 had no effect. The hepatotrophic action of insulin was not altered when the insulin infusate was mixed with transforming growth factor-β or tamoxifen. These experimens show the importance of in vivo in addition to in vitro testing of putative growth control factors. They illustrate how Eck's fistula model can be used to screen for such substances and possibly to help delineate their mechanisms of action.",
author = "Antonio Francavilla and Starzl, {Thomas E.} and Ken Porter and Foglieni, {Carlo Scotti} and Michalopoulos, {George K.} and Guiseppe Carrieri and Jose Trejo and Alessandro Azzarone and Michele Barone and Zeng, {Qi Hua}",
year = "1991",
month = "10",
language = "English",
volume = "14",
pages = "665--670",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Inc.",
number = "4 PART 1",

}

TY - JOUR

T1 - Screening for candidate hepatic growth factors by selective portal infusion after canine Eck's fistula

AU - Francavilla, Antonio

AU - Starzl, Thomas E.

AU - Porter, Ken

AU - Foglieni, Carlo Scotti

AU - Michalopoulos, George K.

AU - Carrieri, Guiseppe

AU - Trejo, Jose

AU - Azzarone, Alessandro

AU - Barone, Michele

AU - Zeng, Qi Hua

PY - 1991/10

Y1 - 1991/10

N2 - Completely diverting portacaval shunt (Eck's fistula) in dogs causes hepatocyte atrophy, disruption of hepatocyte organelles, fatty infiltration and lowgrade hyperplasia. The effect of hepatic growth regulatory substances on these changes was assessed by constantly infusing test substances for four postoperative days after Eck's fistula into the detached left portal vein above the shunt. The directly infused left lobes were compared histopathologically with the untreated right lobes. In what has been called an hepatotrophic effect, stimulatory substances prevented the atrophy and increased hepatocyte mitoses. Of the hormones tested, only insulin was strongly hepatotrophic; T3 had a minor effect, and glucagon, prolactin, angiotensin II, vasopressin, norepinephrine and estradiol were inert. Insulin-like growth factor, hepatic stimulatory substance, transforming growth factor-α and hepatocyte growth factor (also known as hematopoietin A) were powerfully hepatotrophic, but epidermal growth factor had a barely discernible effect. Transforming growth factor-β was inhibitory, but tamoxifen, interleukin-1 and interleukin-2 had no effect. The hepatotrophic action of insulin was not altered when the insulin infusate was mixed with transforming growth factor-β or tamoxifen. These experimens show the importance of in vivo in addition to in vitro testing of putative growth control factors. They illustrate how Eck's fistula model can be used to screen for such substances and possibly to help delineate their mechanisms of action.

AB - Completely diverting portacaval shunt (Eck's fistula) in dogs causes hepatocyte atrophy, disruption of hepatocyte organelles, fatty infiltration and lowgrade hyperplasia. The effect of hepatic growth regulatory substances on these changes was assessed by constantly infusing test substances for four postoperative days after Eck's fistula into the detached left portal vein above the shunt. The directly infused left lobes were compared histopathologically with the untreated right lobes. In what has been called an hepatotrophic effect, stimulatory substances prevented the atrophy and increased hepatocyte mitoses. Of the hormones tested, only insulin was strongly hepatotrophic; T3 had a minor effect, and glucagon, prolactin, angiotensin II, vasopressin, norepinephrine and estradiol were inert. Insulin-like growth factor, hepatic stimulatory substance, transforming growth factor-α and hepatocyte growth factor (also known as hematopoietin A) were powerfully hepatotrophic, but epidermal growth factor had a barely discernible effect. Transforming growth factor-β was inhibitory, but tamoxifen, interleukin-1 and interleukin-2 had no effect. The hepatotrophic action of insulin was not altered when the insulin infusate was mixed with transforming growth factor-β or tamoxifen. These experimens show the importance of in vivo in addition to in vitro testing of putative growth control factors. They illustrate how Eck's fistula model can be used to screen for such substances and possibly to help delineate their mechanisms of action.

UR - http://www.scopus.com/inward/record.url?scp=0026077226&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026077226&partnerID=8YFLogxK

M3 - Article

C2 - 1916668

AN - SCOPUS:0026077226

VL - 14

SP - 665

EP - 670

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 4 PART 1

ER -